Teacher Retirement System of Texas Sells 4,759 Shares of Labcorp Holdings Inc. $LH

Key Points

• Teacher Retirement System of Texas reduced its Labcorp stake by 21.5% in Q4, selling 4,759 shares and leaving 17,374 shares valued at about $4.36M at quarter-end.
• Insider selling accelerated: CEO Adam H. Schechter sold 8,705 shares for roughly $2.44M on March 3, and company insiders have sold 16,113 shares totaling about $4.55M over the past 90 days.
• Company and market context: Labcorp beat quarterly EPS ($4.07 vs. $3.95), set FY‑2026 guidance of 17.55–18.25 EPS, holds a consensus “Moderate Buy” target of about $307.20, and declared a quarterly dividend of $0.72 (1.1% yield).

Teacher Retirement System of Texas cut its holdings in Labcorp Holdings Inc. (NYSE:LH - Free Report) by 21.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,374 shares of the medical research company's stock after selling 4,759 shares during the period. Teacher Retirement System of Texas' holdings in Labcorp were worth $4,359,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in LH. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp in the 4th quarter valued at $26,000. JPL Wealth Management LLC bought a new position in shares of Labcorp in the 3rd quarter valued at about $28,000. Eagle Bay Advisors LLC bought a new position in shares of Labcorp in the 4th quarter valued at about $29,000. Motco acquired a new stake in shares of Labcorp in the third quarter valued at about $32,000. Finally, Beacon Financial Strategies CORP acquired a new stake in shares of Labcorp in the fourth quarter valued at about $33,000. Institutional investors and hedge funds own 95.94% of the company's stock.

Insider Activity at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 8,705 shares of the company's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total value of $2,437,051.80. Following the transaction, the chief executive officer directly owned 80,773 shares in the company, valued at $22,613,209.08. The trade was a 9.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $284.91, for a total transaction of $156,130.68. Following the completion of the transaction, the executive vice president directly owned 2,579 shares in the company, valued at $734,782.89. The trade was a 17.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 16,113 shares of company stock valued at $4,547,450 in the last ninety days. Company insiders own 0.84% of the company's stock.

Analyst Ratings Changes

Several brokerages recently commented on LH. Weiss Ratings raised Labcorp from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, February 10th. Evercore reiterated an "outperform" rating and set a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. Wall Street Zen downgraded Labcorp from a "buy" rating to a "hold" rating in a report on Saturday, April 4th. JPMorgan Chase & Co. raised their target price on shares of Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Finally, Robert W. Baird upped their price target on shares of Labcorp from $313.00 to $326.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 18th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, Labcorp currently has a consensus rating of "Moderate Buy" and a consensus target price of $307.20.

Labcorp Price Performance

Shares of NYSE LH opened at $263.43 on Tuesday. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.60. The business's 50 day moving average price is $271.98 and its two-hundred day moving average price is $267.76. The company has a market cap of $21.65 billion, a PE ratio of 25.18, a price-to-earnings-growth ratio of 1.80 and a beta of 1.02. Labcorp Holdings Inc. has a twelve month low of $218.76 and a twelve month high of $293.72.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The company had revenue of $3.52 billion during the quarter, compared to analysts' expectations of $3.56 billion. During the same period last year, the firm posted $3.45 earnings per share. The business's revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. On average, analysts predict that Labcorp Holdings Inc. will post 17.67 EPS for the current year.

Labcorp Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp's payout ratio is 27.53%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp NYSE: LH, is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.